A5041727510- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- Viral-associated cancers and disorders
- Eosinophilic Disorders and Syndromes
- Biomedical Ethics and Regulation
- Insect Resistance and Genetics
- CNS Lymphoma Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Animal Disease Management and Epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Pharmacy and Medical Practices
- Vector-Borne Animal Diseases
- Pneumocystis jirovecii pneumonia detection and treatment
- Diverse Scientific Research Studies
Memorial Sloan Kettering Cancer Center
2024-2025
The University of Texas MD Anderson Cancer Center
2023-2025
Kettering University
2024
7044 Background: As CD19 chimeric antigen receptor T-cell (CAR-T) therapy has shown curative potential in patients (pts) with relapsed/refractory (R/R) LBCL, indications for treatment are expanding. The reported manufacturing failure rate was 1-13% clinical trials, but there is poor understanding of out-of-specification (OOS) products and CAR-T on 2nd apheresis. This study aims to characterize factors associated successful manufacturing. Methods: includes pts R/R LBCL who underwent apheresis...
7571 Background: Burkitt lymphoma (BL) is a rare, but highly aggressive B-cell associated with especially poor outcomes in patients relapsed/refractory disease. Multiple CD19 chimeric antigen receptor (CAR) T-cell products have been FDA approved to treat non-Hodgkin the second-line setting, however little known about CAR responses BL. This multicenter study aims assess real-world among BL treated therapy across United States. Methods: multicenter, retrospective chart review was conducted by...
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL who have received at least 2 prior lines of therapy based on the LOTIS-2 trial. However, there limited data regarding its efficacy real-world setting (RWS). This retrospective study included 21 US centers and evaluated outcomes treated Lonca. Our analysis includes 187 notably higher risk...